Pharma firms hit by EU ruling

The European Union’s highest court has upheld a €52.5m (£42m) antitrust fine levied against AstraZeneca for blocking the entry of cheaper rivals to its then bestseller ulcer drug Losec. The decision is a blow for the British drugmaker and the wider pharmaceutical industry, which will in future have to take greater care not to overstep the mark in protecting branded medicines from cut-price generics.